Kidney Cancer Journal 25
E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
Lancet. 2016; 387(10032): 2008-16.
31. Staehler M, Haseke N, Schoppler G, et al. Carcinoma of the collecting
ducts of Bellini of the kidney: adjuvant chemotherapy followed by
multikinase-inhibition with sunitinib. Eur J Med Res. 2008;13:531–5
32. Armstrong AJ, Halabi S, Eisen T, et al. Everolimus versus sunitinib for
patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a
multicentre, open-label, randomised phase 2 trial. The Lancet Oncology.
2016; 17(3): 378-388.
33. Tanir NM, Jonasch E, Albiges L, et al. Everolimus Versus Sunitinib
Prospective Evaluation in Metastatic Non–Clear Cell Renal Cell Carcinoma
(ESPN): A Randomized Multicenter Phase 2 Trial. European Urology.
2016; 69(5): 866-874.
34. Motzer RJ, Barrios CH, Kim TM, et al. Phase II Randomized Trial
Comparing Sequential First-Line Everolimus and Second-Line Sunitinib
Versus First-Line Sunitinib and Second-Line Everolimus in Patients With
Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 2013;
32(25): 2765-2772.
35. Buti S, Bersanelli M, Maines F, et al. First-line Pazopanib in Nonclear
cell renal cell carcinoma: the Italian Retrospective Multicenter
PANORAMA Study. Clin Genitourin Cancer. 2017; 15(4):e609-e614.
36. Ravaud A, Oudard S, De Fromont M, et al. First-line treatment with
sunitinib for type 1 and type 2 locally advanced or metastatic papillary
renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary
Group. Annals of Oncology. 2015; 26(6): 1123-1128.
37. Escudier B. Molinie V, Bracarda S, et al. Open-label phase 2 trial of
first-line everolimus monotherapy in patients with papillary metastatic
renal cell carcinoma: RAPTOR final analysis. European Journal of Cancer.
2016; 69:226-235.
38. Srinivasan R, et al: Mechanism based targeted therapy for hereditary
leiomyomatosis and renal cell cancer (HLRCC) and sporadic papillary
renal cell carcinoma: interim results from a phase 2 study of
bevacizumab and erlotinib. EORTC-NCI-AACR Symposium on Molecular
Targets and Cancer Therapeutics. Abstract 5. Presented November
19, 2014.
39. Schoffski P. Crizotinib achieves objective responses and long-lasting
disease control in patients with metastatic papillary renal cell carcinoma
type 1 (PRCCC1) with somatic MET mutations. EORTC phase II trial
90101 “CREATE”. Paper presented at: American Association of Cancer
Research Annual Meeting 2016; April 2016; New Orleans, LA.
40. Https://clinicaltrials.gov NCT02761057
41. Choueiri TK, Vaishampyan U, Rosenberg JE, et al. Phase 2 and biomarker
study of the dual MET/VEGFR2 inhibitor foretinib in patients
with papillary renal cell carcinoma. J Clin. Oncol. 2013; 31(2):181-6.
42. Choueiri TK, Plimack E. Arkenau HT et al. Biomarker-based phase II
trial of savolitinib in patients with advanced papillary renal cell cancer.
J Clin Oncol. 2017; 35(26):2993-3001.
43. https://clinicaltrials.gov: NCT03091192
44. https://clinicaltrials.gov NCT02761057
45. Choueiri TK, Fay AP, Gray KP, et al. PD-L1 expression in nonclearcell
renal cell carcinoma. Ann Oncol 2014; 25:2178.
46. https://clinicaltrials.gov NCT02724878
47. Choueiri TK, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib
in metastatic papillary and chromophobe renal cell carcinoma.
Journal of Clinical Oncology. 2008; 26(1): 127-131.
48. Oudard S, Banu E, Viellefond A, et al. Prospective multicenter phase
ii study of gemcitabine plus platinum salt for metastatic collecting duct
carcinoma: results of a getug (Groupe d’Etudes des Tumeurs Uro-Genitales)
study. Journal of Urololgy. 2007; 177: 1698–702.
49. Pecuchet N, Bigot F, Gachet J, et al. Triple combination of bevacizumab,
gemcitabine and platinum salt in metastatic collecting duct
carcinoma. Annals of Oncology. 2013; 24(12): 2963-2967.
50. Strouse JJ, Spevak M, Mack AK, et al. Significant responses to platinum
based chemotherapy in renal medullary carcinoma. Pediatric Blood
Cancer. 2005. 44(4): 407-411.
51. Walsh A, Kelly DR, Vaid YN, et al. Complete response to carboplatin,
gemcitabine, and paclitaxel in a patient with advanced metastatic renal
medullary carcinoma. Pediatric Blood Cancer. 2010; 55(6): 1217-1220.
52. Schaeffer EM, Guzzo TJ, Furge KA et al. Renal medullary carcinoma:
molecular, pathological and clinical evidence for treatment with topoisomerase
inhibiting therapy. BJU Int. 2010 Jul;106(1):62-5.
53. Carden MA, Smith S, Meany H, et al. Platinum plus bortezomib for
the treatment of pediatric renal medullary carcinoma: Two cases. Pediatric
Blood Cancer. 2017. 64(7).
54. Kondagunta GV, Drucker B, Schwartz L, et al. Phase II Trial of Bortezomib
for Patients With Advanced Renal Cell Carcinoma. Journal of Clinical
Oncology. 2004; 22(18): 3720-3725.
55. Ronnen EA, Kondagunta GV, Motzer RJ, et al. Medullary Renal Cell
Carcinoma and Response to Therapy with Bortezomib. Journal of Clinical
Oncology. 2006; 24(9): e14-e14.
56. Choueiri TK, Lim ZD, Hirsch MS, et al. Vascular endothelial growth
factor-targeted therapy for the treatment of adult metastatic Xp11.2
translocation renal cell carcinoma. Cancer. 2010;116:5219.
57. Malouf GG, Camparo P, Oudard S, et al. Targeted agents in metastatic
Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a
report from the Juvenile RCC Network. Ann Oncol. 2010;21:1834-1838.
58. Geynisman, DM. Anti-programmed Cell Death Protein 1 (PD-1) Antibody
Nivolumab Leads to a Dramatic and Rapid Response in Papillary
Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. Eur
Urol. 2015; 68:912.
59. Koshkin VS, Barata PC, Zhang T, et al. Clinical activity of nivolumab
in patients with non-clear cell renal cell carcinoma. Journal for ImmunoTherapy
of Cancer. (2018)6:9. KCJ
/clinicaltrials.gov
/clinicaltrials.gov
/clinicaltrials.gov
/clinicaltrials.gov